Loren Adler

Loren Adler on Twitter

Loren Adler is associate director of the Brookings Schaeffer Initiative for Health Policy. Previously, he served as research director for the Committee for a Responsible Federal Budget and as a senior policy analyst for the Bipartisan Policy Center and Domenici-Rivlin Debt Reduction Task Force. Adler received his bachelor’s degree in mathematical economics from Wesleyan University.

Recent Work

Ground Ambulance Billing and Prices Differ by Ownership Structure

28% of commercially insured emergency ground ambulance transports during the period 2014–17 resulted in a potential surprise bill
Categorized in
- Research
- Journal Articles
Comments on the Request for Information on Medicare

Schaeffer Initiative experts submitted a comment letter responding to a recent request for information (RFI) related to the Medicare Advantage (MA) program

By Loren Adler, Matthew Fiedler, PhD, Richard G. Frank, PhD and Marta Walentynowicz
Categorized in
- USC-Brookings Schaeffer on Health Policy
Dispute Resolution Outcomes for Surprise Bills in Texas

Analysis of cases that went through dispute resolution found the final allowed were largely anchored to the established.
Categorized in
The FDA Could Do More to Promote Generic Competition: Here’s How

USC-Brookings Schaeffer Initiative experts focus on three areas of FDA authority that could be refined to better promote generic competition: the Citizen Petition mechanism; the approval of so-called complex generic drugs; and the phenomenon known as “parking” under the Hatch-Waxman Act.
Categorized in
New Evidence Suggests a Lack of Cost-Shifting in Prescription Drug Markets

Recent legislative efforts to regulate drug prices have reignited debates about the interaction between price setting in public insurance programs and commercial market spending.

By Loren Adler and Benedic Ippolito
Categorized in
- USC-Brookings Schaeffer on Health Policy

Loren Adler's social media accounts

Loren Adler's Bio

Recent Work

Ground Ambulance Billing and Prices Differ by Ownership Structure

Comments on the Request for Information on Medicare

Dispute Resolution Outcomes for Surprise Bills in Texas

The FDA Could Do More to Promote Generic Competition: Here’s How

New Evidence Suggests a Lack of Cost-Shifting in Prescription Drug Markets